Cargando…
Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
BACKGROUND: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. METHODS: I...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248445/ https://www.ncbi.nlm.nih.gov/pubmed/25421010 http://dx.doi.org/10.1186/s12931-014-0149-3 |
_version_ | 1782346804262600704 |
---|---|
author | Geng, Qing Fan, Tao Zhang, Boyou Wang, Wei Xu, Yao Hu, Hao |
author_facet | Geng, Qing Fan, Tao Zhang, Boyou Wang, Wei Xu, Yao Hu, Hao |
author_sort | Geng, Qing |
collection | PubMed |
description | BACKGROUND: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. METHODS: In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs. RESULTS: ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups. CONCLUSIONS: In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results. |
format | Online Article Text |
id | pubmed-4248445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42484452014-12-02 Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer Geng, Qing Fan, Tao Zhang, Boyou Wang, Wei Xu, Yao Hu, Hao Respir Res Research BACKGROUND: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. METHODS: In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs. RESULTS: ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups. CONCLUSIONS: In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results. BioMed Central 2014-11-25 2014 /pmc/articles/PMC4248445/ /pubmed/25421010 http://dx.doi.org/10.1186/s12931-014-0149-3 Text en © Geng et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Geng, Qing Fan, Tao Zhang, Boyou Wang, Wei Xu, Yao Hu, Hao Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
title | Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
title_full | Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
title_fullStr | Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
title_full_unstemmed | Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
title_short | Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
title_sort | five micrornas in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248445/ https://www.ncbi.nlm.nih.gov/pubmed/25421010 http://dx.doi.org/10.1186/s12931-014-0149-3 |
work_keys_str_mv | AT gengqing fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer AT fantao fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer AT zhangboyou fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer AT wangwei fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer AT xuyao fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer AT huhao fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer |